Immunology

The Immunology Department at St James’s hospital  runs a number of both investigator-led and industry centered drug trials in Immunology.

Current Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
CDZAn open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical Trial (NCT02435173) (2014-003876-22)NovartisCommercial: Industry
HyQviaNon-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQviaObservational-non invasive (NCT01034969)BaxaltaCommercial: Industry
IOS registryIcatibant Outcome Survey (IOS) registry protocolObservational-non invasive (NCT01034969)ShireCommercial: Industry
ABT in UrticariaHealth through attention based training (ABT) for patients in SJH with urticariaObservational-non invasiveNon-commercial: Academic
SOLAR study A Phase IIIb, Randomized, Multicenter, Active-controlled,Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed Clinical trial ViiV Healthcare Commercial: Industry
Santorini Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI) Observational-non invasive Daiichi Sankyo Europe GmbH Commercial: Industry
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
CDZ OLEAn open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical Trial (NCT02859727)(2016-000468-41)NovartisCommercial: Industry